Key result
Admission LDL-C <2.6 mmol/L in acute coronary syndrome patients was associated with higher major adverse cardiovascular events compared to LDL-C ≥2.6 mmol/L.
Why the study?
Does admission LDL-C <2.6 mmol/L compared to ≥2.6 mmol/L associate with short-term major adverse cardiovascular events in patients hospitalized with acute coronary syndrome?
Cohort (n=79)
No
Does admission LDL-C <2.6 mmol/L compared to ≥2.6 mmol/L associate with short-term major adverse cardiovascular events in patients hospitalized with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
In patients hospitalized with acute coronary syndrome, lower admission LDL-C (<2.6 mmol/L) is paradoxically associated with higher rates of short-term MACE, likely driven by a higher baseline burden of comorbidities and prior statin use.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Strinić et al. (2026) conducted a cohort in Acute coronary syndrome (n=79). Admission LDL cholesterol <2.6 mmol/L vs. Admission LDL cholesterol ≥2.6 mmol/L was evaluated on Major adverse cardiovascular events (MACE: stroke, reinfarction, cardiovascular death, or heart-failure hospitalization) (p=0.008). Admission LDL-C <2.6 mmol/L in acute coronary syndrome patients was associated with higher major adverse cardiovascular events compared to LDL-C ≥2.6 mmol/L.
Synapse has enriched 10 related papers. Consider them for comparative context: